Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Change in Accured Expenses (2018 - 2025)

Cyclerion Therapeutics has reported Change in Accured Expenses over the past 7 years, most recently at $85000.0 for Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 140.48% year-over-year to $85000.0; the TTM value through Sep 2025 reached $27000.0, up 103.21%, while the annual FY2024 figure was -$515000.0, 67.49% up from the prior year.
  • Change in Accured Expenses for Q3 2025 was $85000.0 at Cyclerion Therapeutics, up from -$138000.0 in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $462000.0 in Q2 2023 and troughed at -$3.4 million in Q1 2021.
  • A 5-year average of -$362526.3 and a median of -$186000.0 in 2022 define the central range for Change in Accured Expenses.
  • On a YoY basis, Change in Accured Expenses climbed as much as 527.78% in 2023 and fell as far as 636.36% in 2023.
  • Year by year, Change in Accured Expenses stood at -$281000.0 in 2021, then surged by 33.81% to -$186000.0 in 2022, then crashed by 97.31% to -$367000.0 in 2023, then soared by 88.83% to -$41000.0 in 2024, then skyrocketed by 307.32% to $85000.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for CYCN at $85000.0 in Q3 2025, -$138000.0 in Q2 2025, and $121000.0 in Q1 2025.